The interaction of psychopharmacology and psychoanalysis in the borderline patient.
D000339:Affect; D000786:Anger; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001883:Borderline Personality Disorder / Q000175:diagnosis* / Q000188:drug therapy / Q000523:psychology; D002746:Chlorpromazine / Q000494:pharmacology; D002986:Clinical Trials as Topic; D003863:Depression; D004311:Double-Blind Method; D004532:Ego; D005260:Female; D006801:Humans; D007099:Imipramine / Q000627:therapeutic use; D008094:Lithium / Q000627:therapeutic use; D008297:Male; D008722:Methods; D010554:Personality Disorders / Q000175:diagnosis*; D010672:Phenytoin / Q000627:therapeutic use; D011352:Procyclidine / Q000008:administration & dosage; D011573:Psychoanalytic Interpretation; D014191:Tranylcypromine / Q000627:therapeutic use; D014268:Trifluoperazine / Q000627:therapeutic use
D014150:Antipsychotic Agents; D014268:Trifluoperazine; D014191:Tranylcypromine; D010672:Phenytoin; D008094:Lithium; D011352:Procyclidine; D007099:Imipramine; D002746:Chlorpromazine